Extendicare Inc. (TSE:EXE – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday after Natl Bk Canada upgraded the stock to a strong-buy rating. The company traded as high as C$22.16 and last traded at C$22.08, with a volume of 159077 shares traded. The stock had previously closed at C$20.99.
EXE has been the topic of several other reports. TD Securities upped their price objective on shares of Extendicare from C$15.00 to C$19.00 in a research note on Thursday, November 13th. National Bankshares increased their price target on Extendicare from C$21.50 to C$24.50 and gave the stock an “outperform” rating in a research report on Wednesday. Cormark raised their price target on Extendicare from C$25.00 to C$30.00 in a report on Wednesday. CIBC boosted their price objective on Extendicare from C$18.00 to C$22.00 in a research note on Thursday, November 13th. Finally, BMO Capital Markets raised their target price on Extendicare from C$15.00 to C$21.00 in a research note on Monday, November 17th. Three research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of C$23.30.
Get Our Latest Analysis on Extendicare
Extendicare Stock Performance
Extendicare Announces Dividend
The business also recently declared a monthly dividend, which was paid on Monday, November 17th. Stockholders of record on Monday, November 17th were paid a $0.042 dividend. The ex-dividend date of this dividend was Friday, October 31st. This represents a c) dividend on an annualized basis and a dividend yield of 2.3%. Extendicare’s dividend payout ratio is 46.60%.
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Recommended Stories
- Five stocks we like better than Extendicare
- Investing in Travel Stocks Benefits
- Can Alibaba’s Big Bets Pay Off After a Breakout Year?
- How to Buy Gold Stock and Invest in Gold
- How Accenture’s OpenAI Partnership Turns AI Hype Into Profits
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Battle of the Big-Upside Tech Names: HUBS vs. NBIS vs. TEAM
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
